Wearing-off symptoms during standard and extended natalizumab dosing intervals: Experiences from the COVID-19 pandemic

Natalizumab effectively prevents disease activity in relapsing-remitting multiple sclerosis, but many treated patients report subjective wearing-off symptoms at the end of the 4-week interval between infusions. Extended interval dosing (EID) is a promising strategy to mitigate the risk of natalizuma...

Descripción completa

Detalles Bibliográficos
Autores principales: Bringeland, Gerd Haga, Blaser, Nello, Myhr, Kjell-Morten, Vedeler, Christian Alexander, Gavasso, Sonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2021
Materias:
Clinical Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445695/
https://www.ncbi.nlm.nih.gov/pubmed/34474301
http://dx.doi.org/10.1016/j.jns.2021.117622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445695/
https://www.ncbi.nlm.nih.gov/pubmed/34474301
http://dx.doi.org/10.1016/j.jns.2021.117622

Ejemplares similares